Close Menu

NEW YORK (GenomeWeb) – Canadian RNAi drug developer Tekmira Pharmaceuticals has announced that it has agreed to merge with US-based OnCore Biopharma to create a new company focused on an oral cure for hepatitis B virus infection.

As a result of the transaction, which is expected to close in the first half of this year, Tekmira will shift away from being a pure-play RNAi drug firm aiming to use the gene-silencing technology to treat multiple different diseases to a company focused on developing multiple technologies against a single indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.